SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ATHE

Alterity Therapeutics Ltd (NASDAQ:ATHE)

AU · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.52-$0.14 (-8.16%)
 
Market cap
$25.8M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 29, 2003
Market Cap$25.75M-57.2%
Revenue (ttm)$0-31.5%
Net Income-$23.42M-8.0%
EPS-$1.32+58.3%
Shares Out16.94M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,240
Open$1.59
Previous Close$1.66
Day's Range$1.51 - $1.64
52-Week Range$1.51 - $5.89
Betan/a
AnalystsBuy
Price Target$8.00(+426.32%)
Earnings DateMar 4, 2027
-8.16% (1D)
No price history available.

About ATHE

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

Address
500 Collins Street, Melbourne, VIC, 3000, AU
Market Cap
26 million
Employees
11
Industrial Classification
Biotechnology

Alterity Therapeutics Ltd Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
18th Percentile Overall Score
ATHE InsiderScore:54 / 99

Alterity Therapeutics Ltd scored higher than 18% of companies evaluated by InsiderBuying, and ranked 64th out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Alterity Therapeutics Ltd bought $23.8K of stock across 1 purchase in the last 90 days, the largest of them $23.8K.

Stake Increase

The average purchase added about 33% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$23.81K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From ATHE’s reported statements · Q2 2026 (trailing 12 months)

Next catalysts

1 Day
-8.16%
5 Days
-22.45%
1 Month
-29.30%
6 Months
-63.29%
1 Year
-57.18%

$ATHE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ATHE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ATHE's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ATHE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ATHE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ATHE from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ATHE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
24.41
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$23.81K
Distinct Buyers
1

Insider Score Trend Over Time

+15.2 since Sep 24
0255075100Sep 24 — Insider Score 37.4Sep 25 — Insider Score 64.3Sep 26 — Insider Score 63.9Sep 27 — Insider Score 64.0Sep 28 — Insider Score 65.0Sep 29 — Insider Score 63.5Sep 30 — Insider Score 63.2Oct 1 — Insider Score 63.4Oct 2 — Insider Score 39.0Oct 3 — Insider Score 63.0Oct 4 — Insider Score 63.3Oct 5 — Insider Score 63.4Oct 6 — Insider Score 62.5Oct 7 — Insider Score 62.0Oct 8 — Insider Score 61.9Oct 9 — Insider Score 61.8Oct 10 — Insider Score 61.3Oct 11 — Insider Score 62.5Oct 12 — Insider Score 62.5Oct 13 — Insider Score 62.3Oct 14 — Insider Score 62.2Oct 15 — Insider Score 62.1Oct 16 — Insider Score 62.0Oct 17 — Insider Score 61.8Oct 18 — Insider Score 62.2Oct 19 — Insider Score 62.9Oct 20 — Insider Score 63.1Oct 21 — Insider Score 62.9Oct 22 — Insider Score 63.0Oct 23 — Insider Score 62.9Oct 24 — Insider Score 62.8Oct 25 — Insider Score 62.5Oct 26 — Insider Score 62.5Oct 27 — Insider Score 62.6Oct 28 — Insider Score 62.6Oct 29 — Insider Score 62.6Oct 30 — Insider Score 61.6Oct 31 — Insider Score 61.2Nov 1 — Insider Score 61.7Nov 2 — Insider Score 61.8Nov 3 — Insider Score 61.2Nov 4 — Insider Score 59.8Nov 5 — Insider Score 60.3Nov 6 — Insider Score 58.7Nov 7 — Insider Score 58.1Nov 8 — Insider Score 59.0Nov 9 — Insider Score 60.5Nov 10 — Insider Score 58.3Nov 11 — Insider Score 58.7Nov 12 — Insider Score 58.5Nov 13 — Insider Score 57.4Nov 14 — Insider Score 56.6Nov 15 — Insider Score 57.1Nov 16 — Insider Score 57.0Nov 17 — Insider Score 54.8Nov 18 — Insider Score 54.1Nov 19 — Insider Score 53.2Nov 20 — Insider Score 52.6Nov 21 — Insider Score 52.0Nov 22 — Insider Score 52.6Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.